SCHEMBL1851999

SCHEMBL1851999

CC(C)(C)OC(=O)N1CCOC(C(=O)Nc2c(C(N)=O)oc3ccc(Br)cc23)C1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.43
MAPT P10636 2/20 0.43
TSHR P16473 3/20 0.41
BACE1 P56817 1/20 0.41
EPHA2 P29317 2/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
ALDH1A1 P00352 5/20 0.39
MEN1 O00255 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 4/20 0.38
HPGD P15428 2/20 0.38
HSD17B10 Q99714 1/20 0.38
HTT P42858 1/20 0.38
LMNA P02545 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CASP6 P55212 1/20 0.37
USP30 Q70CQ3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1850058 0.86 ALDH1A1 (0.48) KMT2AMAPTTSHRBACE1NPC1
SCHEMBL1851581 0.85 NPC1 (0.51) KMT2AMAPTTSHRBACE1NPC1
SCHEMBL1851938 0.85 TSHR (0.51) KMT2AMAPTTSHRBACE1NPC1
SCHEMBL1849864 0.82 EPHA2 (0.47) KMT2AMAPTTSHRBACE1EPHA2
SCHEMBL1854752 0.81 USP30 (0.47) KMT2AMAPTTSHRBACE1NPC1
SCHEMBL1851649 0.81 USP30 (0.47) KMT2AMAPTTSHRBACE1NPC1
SCHEMBL1854809 0.79 KMT2A (0.44) KMT2AMAPTTSHRBACE1NPC1
SCHEMBL1854807 0.79 KMT2A (0.44) KMT2AMAPTTSHRBACE1NPC1
SCHEMBL1850141 0.79 USP30 (0.53) KMT2AMAPTTSHRNPC1RAB9A
SCHEMBL1851819 0.79 USP30 (0.53) KMT2AMAPTTSHRNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097419-B1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS INC (US) 2011-05-25 EP disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
EP-2097419-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS Exelixis, Inc. (US) 2009-09-09 EP disclosed
WO-2009086264-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS, INC. (US) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247559-A1 Benzofuropyrimidinones F12, BRI3BP, BRD1 KMT2A 2152/4885MAPT 1941/4885TSHR 1203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.